No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
SBP-101 Sensitive: B - Late Trials
|
SBP-101 Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine Sensitive: B - Late Trials
|
gemcitabine Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine + capecitabine Sensitive: B - Late Trials
|
gemcitabine + capecitabine Sensitive: B - Late Trials
|
CCL11 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
CCL11 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
tertomotide Sensitive: B - Late Trials
|
tertomotide Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
CEND-1 Sensitive: B - Late Trials
|
CEND-1 Sensitive: B - Late Trials
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials
|
gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
5-fluorouracil + oxaliplatin Sensitive: B - Late Trials
|
5-fluorouracil + oxaliplatin Sensitive: B - Late Trials
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
ATM mutation
|
Pancreatic Ductal Adenocarcinoma
|
ATM mutation
|
Pancreatic Ductal Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria
|
HGF-H
|
Pancreatic Ductal Adenocarcinoma
|
HGF-H
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Resistant: C3 – Early Trials
|
FOLFIRINOX Resistant: C3 – Early Trials
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
BRCA1 mutation + BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation + BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FANCF mutation
|
Pancreatic Ductal Adenocarcinoma
|
FANCF mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
MSH2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
MSH2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
DDR
|
Pancreatic Ductal Adenocarcinoma
|
DDR
|
Pancreatic Ductal Adenocarcinoma
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
C3M/PRO-C3 ratio elevation
|
Pancreatic Ductal Adenocarcinoma
|
C3M/PRO-C3 ratio elevation
|
Pancreatic Ductal Adenocarcinoma
|
PEGPH20 Sensitive: C3 – Early Trials
|
PEGPH20 Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
GATA6 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
GATA6 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
leucovorin calcium Resistant: C3 – Early Trials
|
leucovorin calcium Resistant: C3 – Early Trials
|
GATA6 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
GATA6 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
5-fluorouracil Resistant: C3 – Early Trials
|
5-fluorouracil Resistant: C3 – Early Trials
|
GATA6 expression
|
Pancreatic Ductal Adenocarcinoma
|
GATA6 expression
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine Resistant: C3 – Early Trials
|
gemcitabine Resistant: C3 – Early Trials
|
LAMC2 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
LAMC2 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine Resistant: C3 – Early Trials
|
gemcitabine Resistant: C3 – Early Trials
|
ATM mutation
|
Pancreatic Ductal Adenocarcinoma
|
ATM mutation
|
Pancreatic Ductal Adenocarcinoma
|
durvalumab + gemcitabine + CP-675206 Sensitive: C3 – Early Trials
|
durvalumab + gemcitabine + CP-675206 Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Pancreatic Ductal Adenocarcinoma
|
ARID1A mutation
|
Pancreatic Ductal Adenocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Pancreatic Ductal Adenocarcinoma
|
PD-L1 expression
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab + trametinib Sensitive: C3 – Early Trials
|
pembrolizumab + trametinib Sensitive: C3 – Early Trials
|
GATA6 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
GATA6 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Resistant: C3 – Early Trials
|
FOLFIRINOX Resistant: C3 – Early Trials
|
MUC1 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
MUC1 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine Sensitive: C3 – Early Trials
|
gemcitabine Sensitive: C3 – Early Trials
|
CLDN18.2 positive
|
Pancreatic Ductal Adenocarcinoma
|
CLDN18.2 positive
|
Pancreatic Ductal Adenocarcinoma
|
CT041 Sensitive: C3 – Early Trials
|
CT041 Sensitive: C3 – Early Trials
|
CAV1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
CAV1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Resistant: C3 – Early Trials
|
gemcitabine + albumin-bound paclitaxel Resistant: C3 – Early Trials
|
MAP2K1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
MAP2K1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
PD-L1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
MAP2K2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
MAP2K2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Pancreatic Ductal Adenocarcinoma
|
PIK3CA mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
RNF43 mutation
|
Pancreatic Ductal Adenocarcinoma
|
RNF43 mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
MRTX849 Sensitive: C3 – Early Trials
|
MRTX849 Sensitive: C3 – Early Trials
|
TP53 mutation + KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
TP53 mutation + KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
KRAS mutation + PD-L1 expression
|
Pancreatic Ductal Adenocarcinoma
|
KRAS mutation + PD-L1 expression
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab + trametinib Sensitive: C3 – Early Trials
|
pembrolizumab + trametinib Sensitive: C3 – Early Trials
|
ATP1B1-NRG1 fusion
|
Pancreatic Ductal Adenocarcinoma
|
ATP1B1-NRG1 fusion
|
Pancreatic Ductal Adenocarcinoma
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|
APP-NRG1 fusion
|
Pancreatic Ductal Adenocarcinoma
|
APP-NRG1 fusion
|
Pancreatic Ductal Adenocarcinoma
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|
FGFR1 T141R
|
Pancreatic Ductal Adenocarcinoma
|
FGFR1 T141R
|
Pancreatic Ductal Adenocarcinoma
|
crizotinib Resistant: C4 – Case Studies
|
crizotinib Resistant: C4 – Case Studies
|
FGFR1 T141R
|
Pancreatic Ductal Adenocarcinoma
|
FGFR1 T141R
|
Pancreatic Ductal Adenocarcinoma
|
alectinib Sensitive: C4 – Case Studies
|
alectinib Sensitive: C4 – Case Studies
|
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
|
Pancreatic Ductal Adenocarcinoma
|
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
|
Pancreatic Ductal Adenocarcinoma
|
lorlatinib Sensitive: C4 – Case Studies
|
lorlatinib Sensitive: C4 – Case Studies
|
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
|
Pancreatic Ductal Adenocarcinoma
|
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Resistant: C4 – Case Studies
|
FOLFIRINOX Resistant: C4 – Case Studies
|
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
|
Pancreatic Ductal Adenocarcinoma
|
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
|
Pancreatic Ductal Adenocarcinoma
|
alectinib Resistant: C4 – Case Studies
|
alectinib Resistant: C4 – Case Studies
|
MSI-H/dMMR + TMB-H + PD-L1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
MSI-H/dMMR + TMB-H + PD-L1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
BRCA1 mutation + TMB-H
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation + TMB-H
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab + olaparib Sensitive: C4 – Case Studies
|
pembrolizumab + olaparib Sensitive: C4 – Case Studies
|
BRAF V600E
|
Pancreatic Ductal Adenocarcinoma
|
BRAF V600E
|
Pancreatic Ductal Adenocarcinoma
|
trametinib + vemurafenib Sensitive: C4 – Case Studies
|
trametinib + vemurafenib Sensitive: C4 – Case Studies
|
TLE2 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
TLE2 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine Sensitive: D – Preclinical
|
gemcitabine Sensitive: D – Preclinical
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
BAL3833 Sensitive: D – Preclinical
|
BAL3833 Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
GANT1 Sensitive: D – Preclinical
|
GANT1 Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
GANT61 Sensitive: D – Preclinical
|
GANT61 Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical
|
Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
cyclopamine Sensitive: D – Preclinical
|
cyclopamine Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
sonidegib Sensitive: D – Preclinical
|
sonidegib Sensitive: D – Preclinical
|
ASS1 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
ASS1 underexpression
|
Pancreatic Ductal Adenocarcinoma
|
panobinostat + pegargiminase Sensitive: D – Preclinical
|
panobinostat + pegargiminase Sensitive: D – Preclinical
|
TMB-L
|
Pancreatic Ductal Adenocarcinoma
|
TMB-L
|
Pancreatic Ductal Adenocarcinoma
|
trametinib + Torin1 Sensitive: D – Preclinical
|
trametinib + Torin1 Sensitive: D – Preclinical
|
MUC1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
MUC1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
BBI608 Sensitive: D – Preclinical
|
BBI608 Sensitive: D – Preclinical
|
CDKN2A deletion
|
Pancreatic Ductal Adenocarcinoma
|
CDKN2A deletion
|
Pancreatic Ductal Adenocarcinoma
|
BET inhibitor + CDK inhibitor Sensitive: D – Preclinical
|
BET inhibitor + CDK inhibitor Sensitive: D – Preclinical
|
TP53 mutation
|
Pancreatic Ductal Adenocarcinoma
|
TP53 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FL118 Sensitive: D – Preclinical
|
FL118 Sensitive: D – Preclinical
|
DDX5 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
DDX5 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
FL118 Sensitive: D – Preclinical
|
FL118 Sensitive: D – Preclinical
|
GLI1 expression
|
Pancreatic Ductal Adenocarcinoma
|
GLI1 expression
|
Pancreatic Ductal Adenocarcinoma
|
sonidegib Sensitive: D – Preclinical
|
sonidegib Sensitive: D – Preclinical
|
SIRT1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
SIRT1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
gefitinib Sensitive: D – Preclinical
|
gefitinib Sensitive: D – Preclinical
|
BRCA mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA mutation
|
Pancreatic Ductal Adenocarcinoma
|
PARP inhibitor Sensitive: D – Preclinical
|
PARP inhibitor Sensitive: D – Preclinical
|
KRAS G12D + Chr del(9)(p21)
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12D + Chr del(9)(p21)
|
Pancreatic Ductal Adenocarcinoma
|
palbociclib Resistant: D – Preclinical
|
palbociclib Resistant: D – Preclinical
|
CD276 expression
|
Pancreatic Ductal Adenocarcinoma
|
CD276 expression
|
Pancreatic Ductal Adenocarcinoma
|
B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical
|
B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical
|
SLC3A2-NRG1 fusion
|
Pancreatic Ductal Adenocarcinoma
|
SLC3A2-NRG1 fusion
|
Pancreatic Ductal Adenocarcinoma
|
MM-121 Sensitive: D – Preclinical
|
MM-121 Sensitive: D – Preclinical
|
ATP1B1-NRG1 fusion
|
Pancreatic Ductal Adenocarcinoma
|
ATP1B1-NRG1 fusion
|
Pancreatic Ductal Adenocarcinoma
|
MM-121 Sensitive: D – Preclinical
|
MM-121 Sensitive: D – Preclinical
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
sotorasib + selinexor Sensitive: D – Preclinical
|
sotorasib + selinexor Sensitive: D – Preclinical
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
selinexor + MRTX1257 Sensitive: D – Preclinical
|
selinexor + MRTX1257 Sensitive: D – Preclinical
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
RMC-6236 Sensitive: D – Preclinical
|
RMC-6236 Sensitive: D – Preclinical
|
MYC overexpression
|
Pancreatic Ductal Adenocarcinoma
|
MYC overexpression
|
Pancreatic Ductal Adenocarcinoma
|
WB100 Sensitive: D – Preclinical
|
WB100 Sensitive: D – Preclinical
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
ASN007 + ERAS-601 Sensitive: D – Preclinical
|
ASN007 + ERAS-601 Sensitive: D – Preclinical
|
CDKN2A deletion
|
Pancreatic Ductal Adenocarcinoma
|
CDKN2A deletion
|
Pancreatic Ductal Adenocarcinoma
|
palbociclib + JQ-1 Sensitive: D – Preclinical
|
palbociclib + JQ-1 Sensitive: D – Preclinical
|
KRAS G12D
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12D
|
Pancreatic Ductal Adenocarcinoma
|
trametinib + BI-3406 Sensitive: D – Preclinical
|
trametinib + BI-3406 Sensitive: D – Preclinical
|
KRAS G12D
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12D
|
Pancreatic Ductal Adenocarcinoma
|
MRTX1133 + BI 894999 + dBET6 Sensitive: D – Preclinical
|
MRTX1133 + BI 894999 + dBET6 Sensitive: D – Preclinical
|